Stockscreener 앱 받기
7.50
0.79%
-0.06
시간 외 거래:
7.53
0.03
+0.40%
전일 마감가:
$7.56
열려 있는:
$7.61
하루 거래량:
22,519
Relative Volume:
0.85
시가총액:
$50.86M
수익:
-
순이익/손실:
$-71.37M
주가수익비율:
-0.6958
EPS:
-10.7782
순현금흐름:
$-46.62M
1주 성능:
-5.42%
1개월 성능:
-7.75%
6개월 성능:
-32.40%
1년 성능:
-73.76%
1일 변동 폭
$7.50
$7.745
1주일 범위
$7.50
$8.06
52주 변동 폭
$5.67
$33.83
인스틸 바이오 Stock (TIL) Company Profile
명칭
Instil Bio Inc
전화
(972) 499-3350
주소
3963 MAPLE AVENUE, DALLAS
Compare TIL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
7.50 | 50.86M | 0 | -71.37M | -46.62M | -10.78 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
인스틸 바이오 Stock (TIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2026-01-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Perform |
| 2024-04-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-11-01 | 다운그레이드 | Truist | Buy → Hold |
| 2021-08-13 | 개시 | Robert W. Baird | Outperform |
| 2021-04-13 | 개시 | Cowen | Outperform |
| 2021-04-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-04-13 | 개시 | Truist | Buy |
모두보기
인스틸 바이오 주식(TIL)의 최신 뉴스
Behavioral Patterns of TIL and Institutional Flows - Stock Traders Daily
Instil Bio Inc (TIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Instil Bio Inc (TIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Instil Bio Inc (TIL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Instil Bio Inc (TIL) Institutional Confidence - TradingKey
Instil Bio Inc (TIL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Instil Bio Inc (TIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Instil Bio Inc (TIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Instil Bio Inc (TIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Instil Bio (TIL) director awarded stock options for 6,500 shares at $7.93 - Stock Titan
Instil Bio (NASDAQ: TIL) director receives grant of 6,500 stock options - Stock Titan
Instil Bio (TIL) director awarded 6,500 stock options at $7.93 strike - Stock Titan
Instil Bio (TIL) director Gwendolyn Binder awarded 6,500 stock options at $7.93 - Stock Titan
Instil Bio Shareholders Back Directors and Auditor at Meeting - TipRanks
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Instil Bio Inc. (TIL) Edges Lower as Stock Tests Key Support ZoneWave Truncation - newsline.com
Instil Bio Inc. Q1 2026 Earnings: EPS Misses Estimates Amid No RevenueBasic EPS Analysis - newsline.com
TIL Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued R&D Investment Amid No RevenueEPS Growth Rate - newsline.com
(TIL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
TIL Technical Analysis | Trend, Signals & Chart Patterns | INSTIL BIO INC (NASDAQ:TIL) - ChartMill
TIL Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Navigates Early PipelineEstimate Accuracy - newsline.com
How (TIL) Movements Inform Risk Allocation Models - Stock Traders Daily
TIL News | INSTIL BIO INC (NASDAQ:TIL) - ChartMill
TIL Q1 2026 Earnings: Wider-than-Expected Loss Highlights Early-Stage Development ChallengesCapex Guidance - The Legal Advocate
Instil Bio Inc. (TIL) Holds Steady Near Key Support After Modest UptickShort Setup Alerts - The Legal Advocate
Instil Bio Q1 2026 Earnings: EPS Miss as Development-Stage Company Reports No Revenue; Stock Edges UpROA Comparison - The Legal Advocate
Instil Bio Q1 2026 Earnings: EPS Miss Reflects Ongoing R&D InvestmentFinancial Health Score - The Legal Advocate
Instil Bio Inc. (TIL) Q1 2026 Earnings: Wider-Than-Expected Loss as Biotech Continues Pre-Commercial PhaseFree Market Insights - Newser
Instil Bio (TIL) Q1 2026 Results Fall Short — EPS $-0.62, Revenue $N/AStock Idea Network - Newser
Trading Systems Reacting to (TIL) Volatility - Stock Traders Daily
Instil Bio (TIL) Q4 2025 Beat: Revenue $N/A, EPS Exceeds by SignificantMargin Improvement - Newser
Instil Bio Releases Q1 2026 Financial Results - AlphaStreet
Instil Bio, Inc. Reports First Quarter 2026 Financial Results – 8-K Filing Details and Key Highlights - Minichart
Instil Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Instil Bio, Inc. 1Q 2026: Net loss $4.2M, EPS $(0.62) — 10-Q Summary - TradingView
Instil Bio (NASDAQ: TIL) cuts Q1 loss as 2024 loan and going concern risk loom - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027 - Stock Titan
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
BRIEF-Instil Bio Q1 Basic EPS USD -0.62 - TradingView
TradingKey - TradingKey
MSN Money - MSN
Why Instil Bio (TIL) deserves a deeper look right now (Smart Money Flows) 2026-05-08AI Powered Stock Picks - Newser
Instil Bio Inc expected to post a loss of 59 cents a shareEarnings Preview - TradingView
How Instil Bio Inc. (TIL) Affects Rotational Strategy Timing - Stock Traders Daily
The R&D spending story behind Instil Bio (TIL) innovation | Instil Bio posts 41% EPS beat, narrower loss, no revenueDebt/EBITDA - newser.com
Instil Bio posts 41% EPS beat, narrower loss, no revenueFinal Results - The Legal Advocate
Key Growth Drivers | Instil Bio posts 40.9% EPS beat topping analyst estimatesConsensus Forecast - newser.com
Instil Bio (TIL) Stock: Key Growth Drivers | Instil Bio posts 40.9% EPS beat topping analyst estimatesFast Rising Picks - Newser
(TIL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
[ARS] Instil Bio, Inc. SEC Filing - Stock Titan
Instil Bio (NASDAQ: TIL) sets 2026 vote and replaces Deloitte - Stock Titan
인스틸 바이오 (TIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):